Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of eptinezumab for the preventive treatment of migraine

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510183-12-00

Acronym

19140A

Enrollment

330

Registered

2024-04-08

Start date

2021-07-05

Completion date

2025-01-22

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic migraine

Brief summary

Change from baseline in the number of monthly migraine days (MMDs) Timepoint(s) of evaluation of this end point: Weeks 1-12

Detailed description

Response: ≥50% reduction from baseline in MMDs (Weeks 1-12), Response: ≥75% reduction from baseline in MMDs (Weeks 1-4), Response: ≥75% reduction from baseline in MMDs (Weeks 1-12), Migraine rate on the day after dosing (Day 1)

Interventions

DRUGVYEPTI 100 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in the number of monthly migraine days (MMDs) Timepoint(s) of evaluation of this end point: Weeks 1-12	—

Secondary

Measure	Time frame
Response: ≥50% reduction from baseline in MMDs (Weeks 1-12), Response: ≥75% reduction from baseline in MMDs (Weeks 1-4), Response: ≥75% reduction from baseline in MMDs (Weeks 1-12), Migraine rate on the day after dosing (Day 1)	—

Countries

Poland, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026